

## Round Promyelocyte Cells with Round Nuclei: Clues to the Diagnosis of *ZBTB16-RARA* Acute Promyelocytic Leukemia

Yuvarlak Çekirdekçikli Yuvarlak Promyelosit Hücreler: *ZBTB16-RARA* Akut Promyelositik Lösemi Tanısı için İpuçları

Yang Su<sup>1</sup>, Jiwei Zhao<sup>2</sup>, Xiaoming Fan<sup>1</sup>, Wei Yang<sup>3\*</sup>, Jinlin Liu<sup>4\*</sup>


<sup>1</sup>Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Department of Laboratory Medicine, Chengdu, China

<sup>2</sup>Nanjing Lishui District Hospital of Traditional Chinese Medicine, Department of Laboratory Medicine, Nanjing, China

<sup>3</sup>Zhejiang Provincial People's Hospital, Bijie Hospital, Department of Clinical Laboratory, Bijie, Guizhou, China

<sup>4</sup>South China Hospital, Shenzhen University Faculty of Medicine, Department of Clinical Laboratory, Shenzhen, China

\* W.Y. and J.L. are corresponding authors and equally contributed to this study.



**Figure 1.** Peripheral blood and bone marrow smears taken from a patient with *ZBTB16-RARA* acute promyelocytic leukemia. Large distinctive round promyelocyte cells with round nuclei were observed in the peripheral blood (A) and bone marrow (B) (magnification: 1000 $\times$ , Wright-Giemsa staining).

Acute promyelocytic leukemia (APL) is typified by the t(15;17) translocation that leads to the formation of the *PML/RARA* fusion gene and predicts a beneficial response to retinoids [1]. However, approximately 10% of APL cases lack the classic t(15;17), and detection of these variants of APL, which could be retinoid-resistant, is time-consuming [1,2]. Therefore, early discrimination of these variants of APL is extremely important,

making it possible to identify patients who will not respond to retinoid treatment and will need other chemotherapy regimens [1]. Herein, we describe a case of *ZBTB16-RARA* APL characterized by distinctive round promyelocyte cells with round nuclei in the peripheral blood and bone marrow, which could be an early diagnostic clue to this rare variant of APL.



Address for Correspondence/Yazışma Adresi: Jinlin Liu, M.D., PhD, South China Hospital, Shenzhen University Faculty of Medicine, Department of Clinical Laboratory, Shenzhen, China; Wei Yang, M.D., Zhejiang Provincial People's Hospital, Bijie Hospital, Department of Clinical Laboratory, Bijie, Guizhou, China  
Phone : +0086-18823663716  
E-mail: liujinlinhz@163.com, yang623621810@163.com ORCID: orcid.org/0000-0003-0502-4813

Received/Geliş tarihi: May 4, 2023  
Accepted/Kabul tarihi: June 14, 2023



©Copyright 2023 by Turkish Society of Hematology Turkish Journal of Hematology, Published by Galenos Publishing House. Licensed under a Creative Commons Attribution-NonCommercial (CC BY-NC-ND) 4.0 International License.

A 52-year-old male was admitted to our hospital with a 2-month history of fatigue with intermittent back pain. The results of other physical examinations were unremarkable. Initial hematological data revealed a total leukocyte count of  $24.7 \times 10^9/L$  (normal range:  $3.5-9.5 \times 10^9/L$ ), neutrophil count of  $13.4 \times 10^9/L$  (normal range:  $1.8-6.3 \times 10^9/L$ ), hemoglobin of 123 g/L, platelet count of  $203 \times 10^9/L$  (normal range:  $85-303 \times 10^9/L$ ), and 7.4% distinctive promyelocyte cells in the peripheral blood. Interestingly, 15% of the promyelocytes were rounded and also had round nuclei (Figure 1A, black arrow). Coagulation testing indicated fibrinogen of 4.1 g/L (normal range: 1.8-3.5 g/L) and D-dimer of 11.9 mg/L (normal range: 0-0.55 mg/L). Further biochemical screening did not show significant changes. Thus, the above results indicated APL and bone marrow aspiration was performed.

Further bone marrow aspiration illustrated hypercellularity, with a myeloid-to-erythroid ratio of 12:1 and 47% dystrophic promyelocytes. They were irregular and hypergranular, with non-lobed or round nuclei and immature chromatin and nucleoli, occasionally with intracytoplasmic Auer rods. Strikingly, 25% of the dystrophic promyelocytes were round promyelocyte cells with round nuclei (Figure 1B, black arrow). Myeloperoxidase staining was strongly positive for these APL cells. Immunophenotyping indicated a profile of promyelocytic cells (CD117, CD33, cMPO, CD56, and CD9) without other aberrant marker expression. In addition, erythroid cells were repressed to 5% and only six megakaryocytes were noted throughout the smear, indicating that the erythroid and megakaryocytic lineages were affected. Thus, the patient was diagnosed with APL. However, the conventional *PML/RARA* fusion gene was not detected in this case, which was inconsistent with the APL diagnosis. A blood sample was then sent for next-generation sequencing examinations and the results revealed the *ZBTB16-RARA* fusion gene. One month later, the cytogenetic result was  $t(11;17)(q23;q21)$ , which confirmed the patient's APL diagnosis.

This variant *ZBTB16-RARA* translocation is reported in less than 1% of APL cases and is associated with a distinctly worse prognosis than  $t(15;17)$  APL, as these patients fail to respond to the maturation effect of all-trans-retinoic acid [2,3]. Thus, this case highlights the atypical morphological features of promyelocytes [2,3], and particularly the distinctive morphology of round promyelocyte cells with round nuclei, which is critical for the diagnosis of this rare APL variant.

**Keywords:** Round promyelocyte cell, Round nuclei, *ZBTB16-RARA*, Acute promyelocytic leukemia

**Anahtar Sözcükler:** Yuvarlak promyelosit hücreler, Yuvarlak çekirdekçik, *ZBTB16-RARA*, Akut promyelositik lösemi

### Ethics

**Informed Consent:** Written consent was obtained for the patient in this case.

### Authorship Contributions

Concept: L.J.; Design: L.J.; Data Collection or Processing: Y.S., J.Z., X.F.; Analysis or Interpretation: Y.S., J.Z., X.F.; Literature Search: W.Y., J.L.; Writing: W.Y., J.L.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

### References

1. Li H, Xiang X, Ding H, Yu J, Xu J, Yuan Y, Wu Y. Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying *ZBTB16-RARA*. *Br J Haematol* 2022;199:768-771.
2. Lechevalier N, Dulucq S, Bidet A. A case of acute promyelocytic leukaemia with unusual cytological features and a *ZBTB16-RARA* fusion gene. *Br J Haematol* 2016;174:502.
3. Dowse RT, Ireland RM. Variant *ZBTB16-RARA* translocation: morphological changes predict cytogenetic variants of APL. *Blood* 2017;129:2038.